Ken Griffin Summit Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2025 May 15, 2025	BUY	$16.65 - $23.76 $1.32 Million - $1.88 Million	79,300 Added 25.15%	394,600 $7.61 Million
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $2.5 Million - $3.34 Million	-142,500 Reduced 31.13%	315,300 $5.63 Million
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $2.7 Million - $12.5 Million	392,300 Added 598.93%	457,800 $10 Million
Q2 2024 Aug 14, 2024	BUY	$2.39 - $10.92 $147,702 - $674,856	61,800 Added 1670.27%	65,500 $510,000
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $9,180 - $18,252	3,600 Added 3600.0%	3,700 $15,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $167 - $283	100 New	100 $0
Q1 2023 May 15, 2023	SELL	$1.38 - $5.41 $163,530 - $641,085	-118,500 Reduced 93.31%	8,500 $14,000
Q4 2022 Feb 14, 2023	BUY	$0.68 - $5.31 $86,360 - $674,370	127,000 New	127,000 $539,000

239

87.2M

1.84M

3.13M

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.61B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.